TABLE 2

Effect of β2-adrenoceptor agonist/glucocorticoid combinations on CRE-dependent transcription

As described in figure 1, CRE BEAS-2B reporter cells were treated with salmeterol (10 pM to 100 nM), salbutamol (100 pM to 1 μM) and formoterol (1 pM to 10 nM) in the absence and presence of dexamethasone (1 μM). After 6 h, cells were harvested for luciferase activity determination. pEC50 values and the -fold activation (over basal) were determined for each β2-adrenoceptor agonist in the presence or absence of dexamethasone. See Figure 1 and text for further details.


Treatment

N

pEC50

CRE Activation
M -fold
Salmeterol 6 −9.88 ± 0.30 12.5 ± 1.43
Salmeterol + Dexamethasone 6 −9.87 ± 0.50 10.7 ± 1.70
Formoterol 7 −10.62 ± 0.14 13.3 ± 2.02
Formoterol + Dexamethasone 7 −10.16 ± 0.32 12.5 ± 1.36
Salbutamol 6 −7.94 ± 0.28 11.9 ± 1.68
Salmeterol + Dexamethasone
6
−8.18 ± 0.32
11.1 ± 1.73